We are live on ! Find out more
AQST icon

Aquestive Therapeutics
AQST

114 hedge funds and large institutions have $154M invested in Aquestive Therapeutics in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 33 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

212% more call options, than puts

Call options by funds: $1.89M | Put options by funds: $605K

39% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 33

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

3% less funds holding

Funds holding: 117 → 114 (-3)

3.79% less ownership

Funds ownership: 51.37% → 47.57% (-3.8%)

34% less capital invested

Capital invested by funds: $232M → $154M (-$78M)

Holders
114
Holders Change
-3
Holders Change %
-2.56%
% of All Funds
1.5%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
21
Increased
46
Reduced
33
Closed
22
Calls
$1.89M
Puts
$605K
Net Calls
+$1.28M
Net Calls Change
-$3.21M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$3.02M
2
Bank of America
Bank of America
North Carolina
+$2.87M
3
PFCS
Pale Fire Capital SE
Czech Republic
+$2.31M
4
UBS Group
UBS Group
Switzerland
+$1.52M
5
Stifel Financial
Stifel Financial
Missouri
+$1.4M

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$13.5M
2
Invesco
Invesco
Georgia
-$3.41M
3
Franklin Resources
Franklin Resources
California
-$2.91M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.26M
5
DCM
DAFNA Capital Management
California
-$2.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$750K +$32.9K +7,129 +4%
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$690K +$179K +38,842 +25%
LCM
28
Legato Capital Management
California
$664K -$258K -55,947 -23%
Wellington Management Group
29
Wellington Management Group
Massachusetts
$639K -$25.7K -5,579 -3%
Two Sigma Investments
30
Two Sigma Investments
New York
$626K +$194K +42,160 +32%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$611K -$27.7K -6,014 -3%
Osaic Holdings
32
Osaic Holdings
Arizona
$578K +$9.56K +2,073 +1%
SCM
33
Stonepine Capital Management
Oregon
$570K +$738K +160,000 New
CWM
34
Cahill Wealth Management
Michigan
$509K +$507 +110 +0.1%
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
$502K -$653K -141,542 -50%
Raymond James Financial
36
Raymond James Financial
Florida
$498K +$644K +139,591 New
EC
37
EntryPoint Capital
New York
$483K +$517K +112,210 +476%
DCM
38
DAFNA Capital Management
California
$452K -$2.13M -462,561 -78%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$450K +$440K +95,418 +307%
Barclays
40
Barclays
United Kingdom
$423K +$89.5K +19,399 +20%
AQR Capital Management
41
AQR Capital Management
Connecticut
$409K -$72.9K -15,806 -12%
Russell Investments Group
42
Russell Investments Group
United Kingdom
$386K +$187K +40,626 +60%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$381K +$15K +3,259 +3%
Renaissance Technologies
44
Renaissance Technologies
New York
$340K +$308K +66,800 +234%
Millennium Management
45
Millennium Management
New York
$311K +$212K +45,926 +111%
HighTower Advisors
46
HighTower Advisors
Illinois
$284K -$131K -28,377 -26%
Fidelity Investments
47
Fidelity Investments
Massachusetts
$269K +$346K +75,104 +13,882%
JP Morgan Chase
48
JP Morgan Chase
New York
$269K +$140K +30,467 +68%
Creative Planning
49
Creative Planning
Kansas
$268K -$80.5K -17,467 -19%
ECM
50
ExodusPoint Capital Management
New York
$258K +$115K +24,984 +53%
1
2
3 4 5

AQST Hedge Fund Activity: Q4 2024 in Review

114 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2024, worth a combined $154M — down 34% from $232M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of AQST and 21 opened new positions — a net loss of 1 holder — while 33 trimmed existing stakes and 46 added.

The largest buyer was Goldman Sachs, adding an estimated $3.02M. The largest seller was VR Adviser, cutting an estimated $13.5M.

  • 114 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2024, down from 117 in Q3 2024.
  • Funds reported $154M of Aquestive Therapeutics stock for Q4 2024, down 34% quarter-over-quarter.
  • 21 funds opened new Aquestive Therapeutics positions in Q4 2024 and 22 closed out, a net change of -1 holder.
  • The largest Aquestive Therapeutics buyer in Q4 2024 was Goldman Sachs, an estimated $3.02M added.
  • The largest Aquestive Therapeutics seller in Q4 2024 was VR Adviser, an estimated $13.5M sold.

Based on aggregated 13F filings for Q4 2024.